What adolescents and young adults think about medicines for achondroplasia?
2023-03-29Research
A new study is going to take place in the USA to collect the perspectives of adolescents and young adults with achondroplasia about medicine options and choices for achondroplasia.
Pfizer to Discontinue the Development of Recifercept for Achondroplasia
2023-02-06Research
The pharmaceutical company Pfizer has recently decided to discontinue development of the drug Recifercept for the treatment of achondroplasia.
TransConCNP ACcomplisH Trial News and Results
2022-12-14Research
Last month Ascendis Pharma revealed results on the Phase 2 ACcomplisH Trial in children with achondroplasia aged 2-10, showing TransCon CNP's potential to meet patient and caregiver needs for a safe, effective, tolerable, and convenient treatment for this condition.
Research Opportunity: Open to all adolescents (ages 8 to 22) with achondroplasia
2022-11-30Research
A research team at Baylor College of Medicine and Texas Children’s Hospital in the United States is conducting a research study that you may be eligible for!
Research study dedicated to adults with achondroplasia
2022-11-23Research
Inês Alves, ANDO Portugal founder, is leading a doctoral research program by Évora University on "Physical, Biomechanical, Nutritional and Psychological Characterization of adults with Achondroplasia, associated to physical activity, exercise and sports". This is an academic study supported by ANDO Portugal - National Organization for Skeletal Dysplasia.
Parent and HCP Surveys on Clinical Challenges in Managing Achondroplasia in Infancy and Childhood
2022-09-22Research
Ahead of the upcoming workshop on 27th October 2022, 16:30 CET, Clinical Management Challenges in Infants and Young Children with Achondroplasia, EAF is undertaking two surveys to establish the challenges of managing achondroplasia in these age groups: one for parents of children with achondroplasia and one for clinicians.